Incidence, morbidity and 5-year survival of colorectal cancer patients in the Kujawsko-Pomorskie voivodship in 2005-2011, based on data from the National Health Fund.
The incidence, morbidity and 5-year survival rates illustrate the epidemiological situation of colorectal cancer and assess the effectiveness of the treatment. In Poland, the National Health Fund is the payer of benefits. The data related to morbidity, incidence, and 5-year survival may be supplementary to the epidemiological data of the National Cancer Registry. Analysis of benefits granted by NHF in Bydgoszcz to persons with diagnosed colorectal cancer in 2006-2011 including the assessment of incidence, morbidity and 5-year survival of the population in the Kujawsko-Pomorskie province. The study analyzed the benefits recorded in the database of the National Health Fund in Bydgoszcz in 2006-2011 given to patients with colorectal cancer. The Kaplan-Meier method and the gambling rate were used to determine the probability of survival. In 2006-2011 men were offered 10.1% more benefits than women. The most frequent benefits were colorectal cancer (48.9%), rectal cancer (43.8%) and esophageal cancer (7.2%). In total, 50410 benefits were provided. Despite the increase in the number of women in the population, 388 more men died than women. The probability of survival was 46.8 %% and 42.6% for men and women, respectively, and 41.8%, 44.2% and 48.9% for colon cancer, esophageal and rectal folds, respectively. In the Kujawsko-Pomorskie province during the period of 2006-2011 the number of diagnosed colorectal cancers increased as did the overall number of benefits provided.There was also a downward trend for the total number of benefits granted in relation to the trend of the increase in the number of new diagnosed cases. Incidence and morbidity rates were variable, gradually increasing in subsequent years and amounted to 59/100000 and 67/100000, 355/100000 and 408/100000 in 2010 and 2011, respectively. The probability of 5-year survival was 45.2%. Diagnosis of a disease in patients above 69 years of age increased the likelihood of death.